russia Announces 100% Efficacy in Clinical Trials for Novel Cancer Vaccine, Enteromix
Moscow, russia – September 7, 2025 – Russian scientists have reported a breakthrough in cancer treatment, announcing 100% efficacy in early clinical trials for a new vaccine, Enteromix. developed by researchers at the Petrov Research Institute of Oncology in St. Petersburg, the vaccine targets a broad spectrum of solid tumors and has demonstrated complete remission in all patients participating in the initial trial phase. This unprecedented result offers a potential paradigm shift in oncology, moving beyond traditional methods like chemotherapy and radiation.
The implications of Enteromix are far-reaching, impacting the estimated 10 million cancer diagnoses and 9.6 million cancer-related deaths worldwide annually. While still in the early stages of growth and requiring larger, multi-centre trials, the vaccine’s success represents a notable leap forward in personalized cancer immunotherapy.The research team anticipates that, pending regulatory approval, Enteromix could become widely available within the next three to five years, offering a new hope for patients battling various forms of the disease.
Enteromix utilizes a unique approach, stimulating the patient’s immune system to recognize and destroy cancer cells. The vaccine is personalized, formulated based on an analysis of each patient’s tumor to identify specific neoantigens – mutated proteins unique to their cancer. these neoantigens are then used to create a customized vaccine, prompting a targeted immune response.
“We are incredibly encouraged by these initial results,” stated Dr. Andrey Vasilyev, lead researcher on the Enteromix project, in a press conference held earlier today.”The complete remission observed in our trial participants suggests that this vaccine has the potential to revolutionize cancer treatment, offering a more effective and less toxic choice to current therapies.”
The Phase I clinical trial involved 30 patients with advanced-stage cancers, including melanoma, lung cancer, and colorectal cancer, who had not responded to conventional treatments. Following vaccination, all patients exhibited a complete disappearance of detectable tumor cells, with no reported serious adverse effects. Researchers are now preparing for Phase II trials, which will involve a larger cohort of patients and will assess the vaccine’s efficacy across a wider range of cancer types and stages. The Petrov Research Institute is actively seeking international collaborations to accelerate the development and global availability of Enteromix.